Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 716
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT06152575 MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranat… |
Elranatamab | Cancer | Phase 3 | RECRUITING | En attente / non publié | Pfizer | United States, Argentina, Australia, Belgium, Brazil,… | 2024-02-08 → 2027-12-30 | Ouvrir |
| NCT06685848 Comparison of Hemanext ONE® System and Conventional Red Blood Cell Tran… |
Hemanext ONE system | Cancer | Non applicable | ACTIVE_NOT_RECRUITING | En attente / non publié | Hemanext | United States, Norway · Duke University Health System… | 2024-11-29 → 2028-08 | Ouvrir |
| NCT07763210 Lazarus: IT Therapy for ICANS |
Hydrocortisone | Cancer | Phase 2 | NOT_YET_RECRUITING | En attente / non publié | Royal Brompton & Harefield NHS Fo… | United States · Vanderbilt University/Ingram Cancer C… | 2026-10-01 → 2030-10-01 | Ouvrir |
| NCT06459024 IMPACT STREAM — Master Framework For Relapse or Refractory Acute Myeloi… |
IMPACT STREAM — Master Framework … | Cancer | À vérifier | RECRUITING | En attente / non publié | Istituto Romagnolo per lo Studio … | Germany, Italy, Lithuania, Poland, Romania, Spain · A… | 2024-06-28 → 2032-07 | Ouvrir |
| NCT07425054 CHART-AC — ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Tr… |
HPV ctDNA Response based radiation | Cancer | Phase 2 | RECRUITING | En attente / non publié | Jennifer Dorth | United States · Case Comprehensive Cancer Center, Cle… | 2026-06-19 → 2029-01 | Ouvrir |
| NCT06878274 RESCUE — Post-operative Radiotherapy After Neodjuvant Chemo-immunothera… |
Post-operative radiotherapy | Cancer | Phase 2 | RECRUITING | En attente / non publié | Centre hospitalier de l'Universit… | Canada · Centre Hospitalier de l'Universite de Montre… | 2026-01-29 → 2032-02 | Ouvrir |
| NCT05758116 Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Che… |
Tislelizumab | Cancer | Phase 2 | COMPLETED | En attente / non publié | University Health Network, Toronto | China · Peking University Cancer Hospital and Institu… | 2022-07-07 → 2026-06-30 | Ouvrir |
| NCT05748171 A Study to Learn More About the Study Medicine Called Inotuzumab Ozogam… |
Inotuzumab ozogamicin | Cancer | Phase 2 | RECRUITING | En attente / non publié | Pfizer | Austria, Belgium, Czechia, Denmark, Finland, France, … | 2023-05-17 → 2036-05-25 | Ouvrir |
| NCT03502733 Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Pati… |
Biopsy Procedure | Cancer | Phase 1 | ACTIVE_NOT_RECRUITING | En attente / non publié | National Cancer Institute (NCI) | United States · National Cancer Institute Development… | 2018-08-14 → 2027-08-01 | Ouvrir |
| NCT05538130 A Study to Learn About the Study Medicine Called PF-07799544 as Monothe… |
PF-07799544 | Cancer | Phase 1 | RECRUITING | En attente / non publié | Pfizer | United States, Australia, Brazil, Canada, China, Isra… | 2022-11-30 → 2029-06-18 | Ouvrir |
| NCT07318558 TroFuse-021 — A Clinical Trial of Sac-TMT in People With Non-HRD Positi… |
Sacituzumab Tirumotecan | Cancer | Phase 3 | RECRUITING | En attente / non publié | Merck Sharp & Dohme LLC | United States, Argentina, Australia, Austria, Belgium… | 2026-02-16 → 2033-02-25 | Ouvrir |
| NCT04607460 BEAT-Pain — EMG Biofeedback Treatment for Chronic Low Back Pain, Cancer… |
JOGO Digital Therapeutics EMG Bio… | Migraine | Non applicable | COMPLETED | En attente / non publié | Brigham and Women's Hospital | United States · Brigham and Women's Hospital, Chestnu… | 2020-12-03 → 2023-12-30 | Ouvrir |
| NCT07005297 Clinical Genetics Branch Eligibility Screening Survey |
Clinical Genetics Branch Eligibil… | Cancer | À vérifier | NOT_YET_RECRUITING | En attente / non publié | National Cancer Institute (NCI) | United States · National Cancer Institute, Rockville,… | 2026-08-19 → 2036-01-01 | Ouvrir |
| NCT07629258 GW01-200-01 — A Phase I Trial of GW01-200 Tablets in Subjects With Adva… |
GW01-200 | Cancer | Phase 1 | RECRUITING | En attente / non publié | Groovy Medicine (Hangzhou) Ltd. | China · Hebei Cancer Hospital of Chinese Academy of M… | 2026-07-17 → 2029-06 | Ouvrir |
| NCT07764497 HAIP-6192 — Hepatic Arterial Infusion Chemotherapy in Patients With Ino… |
Floxuridine (FUDR) | Cancer | Phase 2 | RECRUITING | En attente / non publié | Sunnybrook Health Sciences Centre | Canada · Sunnybrook Health Sciences Centre, Toronto, … | 2014-07 → 2036-12 | Ouvrir |
| NCT05650749 GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastati… |
GPC2 CAR T cells | Cancer | Phase 1 | ENROLLING_BY_INVITATION | En attente / non publié | Stephan Grupp MD PhD | United States · Children's Hospital of Philadelphia, … | 2023-05-23 → 2030-01-30 | Ouvrir |
| NCT07764432 CHOOSE — Communication and Hospice Online With Optimal Support and Enga… |
CHOOSE — Communication and Hospic… | Cancer | Non applicable | NOT_YET_RECRUITING | En attente / non publié | Washington University School of M… | United States · Washington University School of Medic… | 2027-02-01 → 2031-04-30 | Ouvrir |
| NCT06822543 TROPICAL-1 — A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Car… |
Pembrolizumab | Cancer | Phase 2 | RECRUITING | En attente / non publié | Bristol-Myers Squibb | Brazil · A.C. Camargo Cancer Center, São Paulo, Brazi… | 2025-09-12 → 2028-11-01 | Ouvrir |
| NCT07053020 A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral… |
Cytarabine | Cancer | Phase 1/2 | NOT_YET_RECRUITING | En attente / non publié | Uma Borate | United States · The University of Texas M. D. Anderso… | 2027-12-01 → 2030-06-30 | Ouvrir |
| NCT05464823 Feasibility of Combined Genomics/Transcriptomics for Patients With Lymp… |
Feasibility of Combined Genomics/… | Cancer | Non applicable | ACTIVE_NOT_RECRUITING | En attente / non publié | M.D. Anderson Cancer Center | United States · M D Anderson Cancer Center, Houston, … | 2022-07-07 → 2027-05-12 | Ouvrir |
| NCT06806033 A Study to Evaluate the Optimization of the Cytokine Release Syndrome P… |
Obinutuzumab | Cancer | Phase 2 | RECRUITING | En attente / non publié | Hoffmann-La Roche | United States, Australia, Canada, France, Germany, It… | 2025-03-05 → 2029-03-30 | Ouvrir |
| NCT05083481 A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Eith… |
ASP1570 | Cancer | Phase 1 | TERMINATED | En attente / non publié | Astellas Pharma Global Developmen… | United States, China, France, Japan, Puerto Rico, Spa… | 2021-10-19 → 2026-05-11 | Ouvrir |
| NCT07764601 RM-MA-PD1 — R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lympho… |
Penpulimab | Cancer | Non applicable | NOT_YET_RECRUITING | En attente / non publié | WEI XU | China · The First Affiliated Hospital of Nanjing Medi… | 2026-08 → 2029-08 | Ouvrir |
| NCT06490328 Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer |
DKF-MA102 | Cancer | Phase 3 | COMPLETED | En attente / non publié | Dongkook Pharmaceutical Co., Ltd. | South Korea · ASAN Medical Center, Seoul, South Korea… | 2024-05-30 → 2026-03-09 | Ouvrir |
| NCT07604766 RAINFOL-02 — An Extension Study to Assess the Efficacy of Rina-S Compar… |
Rina-S | Cancer | Phase 3 | RECRUITING | En attente / non publié | Genmab | China · Chongqing University Cancer Hospital - Chongq… | 2026-06-26 → 2028-12 | Ouvrir |